SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-058193
Filing Date
2024-05-13
Accepted
2024-05-13 07:15:36
Documents
76
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q fulc-20240331.htm   iXBRL 10-Q 1842946
2 EX-10.1 fulc-ex10_1.htm EX-10.1 103586
3 EX-31.1 fulc-ex31_1.htm EX-31.1 12197
4 EX-31.2 fulc-ex31_2.htm EX-31.2 12188
5 EX-32.1 fulc-ex32_1.htm EX-32.1 6692
6 EX-32.2 fulc-ex32_2.htm EX-32.2 6131
  Complete submission text file 0000950170-24-058193.txt   7746832

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT fulc-20240331.xsd EX-101.SCH 1246423
79 EXTRACTED XBRL INSTANCE DOCUMENT fulc-20240331_htm.xml XML 1163211
Mailing Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139
Business Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139 617-651-8851
Fulcrum Therapeutics, Inc. (Filer) CIK: 0001680581 (see all company filings)

IRS No.: 474839948 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38978 | Film No.: 24936860
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)